Salix had a $13B offer on the table before accounting problems crashed share price

If it hadn’t been for accounting errors, it’s possible Salix Pharmaceuticals (Nasdaq: SLXP) would have been acquired last year for $205 per share, instead of the $173 per share for which it agreed to sell to Valeant Pharmaceuticals International (NYSE: VRX)...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.